Aspire Biopharma Holdings, Inc. Income Statement
ASBP|1 years of annual SEC 10-K data (FY2025-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data. All figures from audited SEC 10-K filings.
Aspire Biopharma Holdings, Inc. reported $6,202 in revenue and $1M in net loss for FY2025. Its profit margin was -21120.2% in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -33.16 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 |
|---|---|
| Revenue | $6.2K |
| Cost of Revenue | $6.3K |
| Gross Profit | -$116 |
| SG&A Expense | $940.4K |
| R&D Expense | $144.4K |
| Operating Income | -$1.2M |
| Income Tax | $1.0K |
| Net Income | -$1.3M |
| EPS (Diluted) | -$1.90 |
| Shares Outstanding | 690.0K |
| Gross Margin | -1.9% |
| Operating Margin | -19523.9% |
| Profit Margin | -21120.2% |